These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20134266)

  • 1. Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas.
    Nishimura S; Tsuda H; Ito K; Takano M; Terai Y; Jobo T; Kigawa J; Sugiyama T; Yaegashi N; Aoki D
    Int J Gynecol Cancer; 2010 Feb; 20(2):220-6. PubMed ID: 20134266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
    Choi JY; Han HH; Kim YT; Lee JH; Kim BG; Kang S; Cho NH
    Yonsei Med J; 2017 Jan; 58(1):59-66. PubMed ID: 27873496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer.
    Nishimura S; Tsuda H; Nomura H; Kataoka F; Chiyoda T; Tanaka H; Tanaka K; Susumu N; Aoki D
    Eur J Gynaecol Oncol; 2011; 32(2):146-9. PubMed ID: 21614900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
    Lee S; Garner EI; Welch WR; Berkowitz RS; Mok SC
    Gynecol Oncol; 2007 Aug; 106(2):311-7. PubMed ID: 17532031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs.
    Nishimura S; Tsuda H; Ito K; Jobo T; Yaegashi N; Inoue T; Sudo T; Berkowitz RS; Mok SC
    Hum Pathol; 2007 Jan; 38(1):134-9. PubMed ID: 16996567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
    Takaya A; Peng WX; Ishino K; Kudo M; Yamamoto T; Wada R; Takeshita T; Naito Z
    Int J Oncol; 2015 Apr; 46(4):1573-81. PubMed ID: 25633807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
    Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
    APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
    Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
    Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis.
    Higashiguchi A; Yamada T; Susumu N; Mori T; Suzuki A; Aoki D; Sakamoto M
    Cancer Sci; 2007 Mar; 98(3):387-91. PubMed ID: 17270029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.
    Browne A; Sriraksa R; Guney T; Rama N; Van Noorden S; Curry E; Gabra H; Stronach E; El-Bahrawy M
    Cytokine; 2013 Oct; 64(1):413-21. PubMed ID: 23727325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma.
    Oe S; Hasegawa K; Nagase S; Kato R; Torii Y; Udagawa Y
    Int J Gynecol Pathol; 2010 Sep; 29(5):405-10. PubMed ID: 20736762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
    Hazama Y; Moriya T; Sugihara M; Sano R; Shiota M; Nakamura T; Shimoya K
    Int J Gynecol Pathol; 2018 Nov; 37(6):516-524. PubMed ID: 29019869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1.
    Gimm T; Wiese M; Teschemacher B; Deggerich A; Schödel J; Knaup KX; Hackenbeck T; Hellerbrand C; Amann K; Wiesener MS; Höning S; Eckardt KU; Warnecke C
    FASEB J; 2010 Nov; 24(11):4443-58. PubMed ID: 20624928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
    Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
    J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
    PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
    Itamochi H; Oumi N; Oishi T; Taniguchi F; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
    Int J Gynecol Cancer; 2015 May; 25(4):570-6. PubMed ID: 25756405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
    Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
    Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer.
    Liu P; Sun YL; Du J; Hou XS; Meng H
    Int J Gynecol Cancer; 2012 May; 22(4):586-92. PubMed ID: 22266931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.